Lec 18: Dynamics of Adaptive Immunity part 2 Flashcards

1
Q

B cell memory half life is _____ than T cell memory

A

more robust - no significant decline vs 8-15 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

As pathogen starts to clear, antibodies with ______ will continue to capture antigen and interact with effector TH cells, dominating ______ response

A

the highest affinity;
secondary and tertiary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Original Antigenic Sin

A

whatever antigens you respond to the first time are the antigens you will respond to the next time you get the virus, even if it has mutated. Your immune system will ignore other epitopes based on the success it had in clearing the pathogen the first time around

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Recall response to pathogens is based on your _____ infection

A

first

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What happens when memory response ineffectively targets the pathogen?

A

cytokine storm, antibody dependent enhancement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which boosts immunity better - virus first or vaccine first?

A

Virus first - broader range of epitopes for cross reactive immunity and the subsequent times being exposed to the virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antibody escape concept

A

High antibody binding of pathogen does not mean high neutralization of the pathogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How was efficacy of bivalent vaccine?

A

poor, many breakthrough infections of Omicron because it boosted immunity to original strain but due to original antigenic sin, it ignored Omicron epitopes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

IL-12p70 is made up of _____ subunits

A

p35 and p40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

IL-12 and IL-23 share ____ subunit and their receptors share _____

A

p40;
IL-12Rbeta1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

IL-23 is made up of ____ and _____ subunits

A

p19 and p40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IL-12p70 leads to ____ expression and ___ differentiation

A

STAT4;
TH1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IL-23 leads to ____ expression and ____ differentiation

A

STAT1,3,5;
TH17

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

IL12p70 is critical for __ and ___. Continuous IL12p70 is critical for ____

A

NK and CTL;
TH1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

transfer of TH1 memory cells into RAG- and p40- mice leads to protection for ___ mice because they can continue to produce ______

A

RAG-;
IL-12p70

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When WT mice and mice that lack MHC class II are infected with ovalbumin antigen, CTL response is ____ in both after 7 days. After 70 days CTL response is only high in ____ mice. Suggesting ____ is required for long term CD8+ function

A

high;
WT;
CD4 help

17
Q

Expression of ___ determines CD8+ T cell memory response

A

IL7R

18
Q

transgenic mice with transfer of ILR7___ CD8+ T cells had robust expansion of antigen specific CD8+ T cells

A

high

19
Q

Establishment of CD8+ memory is dependent on _______. About ____% of cells present at peak persist as memory cells

A

initial burst;
5%

20
Q

What are important components for long term CTL immunity

A
  • IL7R expression/availability
  • antigen expression on MHC I and II
  • IL12p70 production and maintenance
  • CD4+ help through CD40L
  • big burst during primary induction
  • removing shutdown mechanisms
21
Q

Tregs produce ___, ____, and ____ which participate in signal 3

A

TGFbeta, IL2, IL10

22
Q

___ produced by TH2 and ____ produced by Treg inhibit Th1

A

IL10 and TGFbeta

23
Q

___ produced by TH1 inhibit TH2

A

IFN-gamma

24
Q

One immune checkpoint is Fas. FasL binds to and ___ Fas. Clustering of __ allows Fas to recruits FADD. Clustered ___ of FADD recruit pro-caspase 8 to initiate apoptosis

A

trimerizes;
DD (death domains);
DED (death effector domains

25
Q

Immune checkpoint examples

A

Fas (FasL)
CTLA4 (B.7)
PD-1 (PD-L1)
LAG3 (MHC II)
TIGIT (CD155:PVR)
TIM3 (Galectin-9/HMGB1

KIRs
NKG2A/CD94

26
Q

NKG2A is expressed by ___ cells and is _____ by MHC

A

NK; inhibited

27
Q

_____ binds to CD80/86, stopping CD28 from binding so T cells don’t get signal 2 and die. antibodies can block this brake so T cells can live longer. Exact mechanism is _____

A

CTLA-4
unknown

28
Q

____ is a marker of activation in T cells. ITIMS recruit _____ and ______ which are phosphatases for PI3K and ZAP70 (screw up signal 2)

A

PD-1
SHP1 and SHP2

29
Q

____ is produced by DCs in response to CD4+ help (CD40L)

A

IL-12

30
Q

____ are effective inducers of primary CTL responses. Basically when pathogen is gone, the only antigen left will be ____

A

alphaDC1
on DC

31
Q

When HIV viral load spikes, _____ is made responding to first epitopes. With mutations/new epitopes, there is _____ (don’t make new CTL response)

A

T cell memory;
cross-reaction

32
Q

______ CTL are cross-reactive to natural variants

A

DC1-primed

33
Q

_____ is priming epitope that make IFNgamma and IL2, which downregulate ___ - shut off mechanism. Variant epitope ____ does not do this

A

TLN9;
CD8
PLN9

34
Q

Priming peptide TLN9 has CTL ______ DC. Variant peptide PLN9 has CTL______ DC. This initiates cytokine production, but you can’t generate a new ___ response because ____ cells get in the way leading to chronic inflammation

A

killed
activated
CTL
memory

35
Q

Cross reactive CTL leads to

A

activation and differentiation of pro inflammatory DC

36
Q

DC based vaccine therapies: take ____ monocytes and stimulate with IL4/GMCSF to generate ___. Add antigen to mature along with TNFalpha, IFNgamma, etc and administer ______ DC

A

CD14+;
CD14- immature DC;
mature, programmed DC

37
Q

alpha DC1 have been shown to be useful in treatments for ___ and ____

A

gliomas and melanomas